OKYO Pharma Limited (NASDAQ:OKYO – Get Free Report) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 338,000 shares, a growth of 30.4% from the February 13th total of 259,200 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average daily trading volume, of 150,800 shares, the short-interest ratio is presently 2.2 days.
OKYO Pharma Stock Performance
Shares of OKYO Pharma stock traded down $0.01 during midday trading on Monday, hitting $1.50. The company had a trading volume of 19,914 shares, compared to its average volume of 213,192. The company has a fifty day simple moving average of $1.16 and a 200 day simple moving average of $1.10. OKYO Pharma has a 12-month low of $0.81 and a 12-month high of $1.90.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a research report on Tuesday, February 18th.
OKYO Pharma Company Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Read More
- Five stocks we like better than OKYO Pharma
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Super Micro’s International Presence Makes It a Winning Stock
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
- 3 Warren Buffett Stocks to Buy Now
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.